![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Risk of multiple drug-drug interactions (DDIs) in
HCV patients receiving pangenotypic DAAs (pDAAs):
A complex drug interaction scenario first time
evaluated in German patients
|
|
|
EASL International Liver Congress, June 23-26, 2021
F. Tacke1, G. Niess2, M. Gündogdu2, A. Hintz3, T. Umland3
1Charite - Universitatsmedizin Berlin, Department of Hepatology and Gastroenterology, Berlin, Germany, 2Gilead Sciences GmbH, Martinsried / Munich, Germany; 3Alexander Apotheke, Hamburg, Germany
![0626211](../images/062621/062621-3/0626211.gif)
![0626212](../images/062621/062621-3/0626212.gif)
![0626213](../images/062621/062621-3/0626213.gif)
![0626214](../images/062621/062621-3/0626214.gif)
![0626215](../images/062621/062621-3/0626215.gif)
![0626216copy](../images/062621/062621-3/0626216copy.gif)
![0626217](../images/062621/062621-3/0626217.gif)
![0626218](../images/062621/062621-3/0626218.gif)
![0626219](../images/062621/062621-3/0626219.gif)
![06262110](../images/062621/062621-3/06262110.gif)
![06262111](../images/062621/062621-3/06262111.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|